USE OF SIMETHICONE TO TREAT ULCERATIVE COLITIS
;
treatment of ulcerative proctitis and colitis

colitis foundation of america

 
 
crohn's-and colitis foundation of america

dealing with ulcerative colitis
treatment of colitis ulcerosa
compositions and method
-fo -treatment of ulcerative
colitis
detection and treatment of ulcerative colitis
method of treating ulcerative colitis
method of treating ulcerative colitis with a monoclonal antibody
methods for the treatment of ulcerative colitis
methods of treating established colitis using antibodies
therapeutic agent for ulcerative colitis
therapeutic-and-diagnostic-methods for ulcerative colitis and associated disorders
treating a patient with ulcerative colitis
 
methods of treatment for ulcerative colitis using aminosalicylate
therapeutic agent for ulcerative colitis
therapeutic-and-diagnostic-methods for ulcerative colitis and associated disorders
treating a patient with ulcerative colitis
 
.

fish oils benefit patients with ulcerative colitis
crohn's disease and ulcerative colitis
!!!!
 

 


 Colitis is understood to be the inflammation of the colon. A chronic type of colitis is ulcerative colitis  of an unknown etiology characterized by ulceration of the colon and rectum, with rectal bleeding, mucosal crypt abscesses, inflammatory pseudopolyps, abdominal pain and diarrhea. Ulcerative colitis  frequently causes anemia, hypoproteinemia, and electrolyte imbalance and is less frequently complicated by peritonitis, toxic megacolon or carcinoma of the colon. Ulcerative colitis is frequently treated with various drugs including sulfasalazine. While these treatments are somewhat effective in treating the symptoms, there is a continuing need for additional treatments for this disease, perhaps a treatment which could be used to enhance the efficacy of the existing treatments.

The present invention provides a method of treating ulcerative colitis in a patient through the administration of an effective amount of simethicone. In a preferred embodiment, an effective amount of a second active ingredient for treating ulcerative colitis, such as sulfasalazine is employed. Simethicone is a well known pharmaceutical material which is a mixture of linear siloxane polymers containing repeating units of the formula {--SiO(CH 3 ) 2 --} n stabilized with trimethylsiloxy endblocking units of the formula [(CH 3 ) 3 SiO--], and silicon dioxide. The level of simethicone in the present invention is sufficient to provide treatment of ulcerative colitis. As used herein, treatment of ulcerative colitis is understood to be a reduction in the amount of bleeding in the patient. The present invention contemplates the treatment of a human or animal, through any suitable dosage forms. Suitable forms includes solids, such as tablets or powders, liquids including suspensions, dispersions and solutions and the like. The preferred route of administration of the simethicone is oral administration, although other techniques known in the art may also be employed.

The effective level of simethicone is generally from about 0.5 mg/kg of body weight per day to about 40 mg/kg of body weight per day, preferably from about 1 mg/kg of body weight per day to about 20 mg/kg of body weight per day, and most preferably from about 5 mg/kg of body weight per day to about 10 mg/kg of body weight per day. The present invention can incorporate other known pharmaceutically active ingredients for the treatment of colitis. Specific groups of ingredients which may be used to treat ulcerative colitis include immunosuppressive, antimicrobial, antidiarrheal, and anticholinergic agents. Of the immunosuppressive agents, sulfasalazine is preferred.

Commonly known pharmaceutically acceptable additives for orally-administered drugs such as sweeteners, flavoring agents, dispersants, buffering agents and the like may be included in amounts that do not adversely affect the novel properties of the formulation described and claimed herein. Suitable dispersants include methylcellulose, hydroxymethyl-cellulose, hydroxypropylmethylcellulose, hydroxyethyl-cellulose and the like. Suitable sweeteners include sugar, sorbitol, saccharin, mannitol, glucose, aspartame and the like. Flavoring agents include peppermint, spearmint, cinnamon, vanilla and the like. A more complete listing of appropriate additives can be found in numerous publications including Remington's Encyclopedia. The present invention is surprising and unexpected in that PCT EP95/00973 previously disclosed that polydimethylsiloxane, also known as dimethicone, is effective in association or affinity to the surface structure of the GI tract. The PCT patent application continues that due to the increased adhesion properties of dimethicone, the residence time of an active ingredient in a region of the GI tract can be substantially prolonged if dimethicone is used as a transport or carrier system. This is contrary to the disclosed invention in which simethicone, which as noted above is a combination of polydimethylsiloxane and silicon dioxide, is effective in being transported to the distal regions of gastrointestinal tract. 
 
 
 


There are also herbal medicines which can very effectively treat colitis & ulcerative colitis. Boswellia is an Ayurvedic  (Indian traditional medicine) herb, used as a natural alternative to drugs. Many studies have found that the effectiveness of Boswellia is similar and even superior to sulfasalazine based prescription drugs. (Source Wikipedia: http://en.wikipedia.org/wiki/Ulcerative_colitis. 

We recommend taking a 4 months course of our Boswellia Serrata Extract.
 
 

Order  Boswellia - Shallaki - 4 Months course



  


 

Total of 4 bottles-  of Boswellia - 4 Months course - Taken 2 capusles twice a day.
 
 

U.S.$49/- ONLY.
(All Inclusive) FREE Shipping Worldwide.
 
 

There are NO ADDITIONAL CHARGES. Packing & Shipping is absolutely FREE. We will deliver direct to your door to reach within 12 days from the date of ordering. A signature will be required at the time of delivery. You can give us your daytime work address or Post Box address if no one will be present at home to receive the shipment during daytime. 
 



 

Please use the form below to mail us for any information. We will revert back within 10 hours .


 
Contact us using this form:
Department:
* Name:
* Email:
Company:
Phone:
Message:
A * indicates a field is required


HOME
Boswellia                Colitis                 Sitemap


 
Credit  Card  Processor/online Retailer
RELAXON
1785 O'Brien Road
Columbus, OH-43228
USA
Physical  Shipping  by :
RELAXON 
An  United  States  FDA  Registered  Food  Facility
US  FDA  Registration  Number :    14801626892
USFDA 1993 DSHEA DISCLAIMER : The therapeutic effects of  CYSTONE has not been evaluated by US FDA. CYSTONE  is not intended to diagnose/treat/cure/prevent/mitigate any ailment. Individual results may vary.